BMT Tandem Meetings


San Diego skyline. Photo by Michael Seljos

The 2015 BMT Tandem Meetings took place February 11-15 in San Diego, California.


‘Biodegradable’ CAR may aid transplant in AML

Jen Smith Read Article
Published: 03/06/15

Saad S. Kenderian, MD
Photo courtesy of
BMT Tandem Meetings

Researchers have developed a “biodegradable” chimeric antigen receptor (CAR) T-cell therapy that could potentially serve as a preparative regimen for acute myeloid leukemia (AML) patients undergoing allogeneic transplant. The team created CAR T cells that target CD33 (CART33) and modified them with RNA so the cells would stop expressing CARs over time. In mouse models of AML, the RNA-CART33 cells had an antileukemic effect and induced myeloablation. [Read Article]

Drug shows promise for treating VOD after HSCT

HT Staff Read Article
Published: 03/04/15

Preparing for HSCT
Photo by Chad McNeeley

Results of 3 studies appear to support the use of defibrotide in patients who develop hepatic veno-occlusive disease (VOD) after hematopoietic stem cell transplant (HSCT). Defibrotide is the sodium salt of a complex mixture of single-stranded oligodeoxyribonucleotides derived from porcine mucosal DNA. It has antithrombotic, anti-inflammatory, and anti-ischemic properties. The drug is already approved in Europe to treat VOD and is under investigation for this indication in the US. [Read Article]

Haplo-BMT feasible in high-risk malignancies

Jen Smith Read Article
Published: 02/25/15

Bone marrow harvest
Photo by Chad McNeeley

Haploidentical bone marrow transplant (haplo-BMT) is a feasible option for patients with high-risk hematologic malignancies who don’t have timely access to an HLA-matched donor, according to a speaker at the 2015 BMT Tandem Meetings. Haplo-BMT using myeloablative conditioning, T-cell replete grafts, and post-transplant cyclophosphamide elicited “excellent” rates of engraftment, graft-vs-host disease (GVHD), and transplant-related mortality, said Heather Symons, MD. [Read Article]

Older age doesn’t decrease HRQOL among PBSC donors

Jen Smith Read Article
Published: 02/24/15

PBSC collection
Photo courtesy of Canterbury
District Health Board

New research indicates that older stem cell donors have somewhat poorer overall health before they donate, but their health-related quality of life (HRQOL) post-donation is similar to that of younger donors. In fact, the older donors included in this study actually fared better than their younger counterparts in some respects. Galen E. Switzer, PhD, of the University of Pittsburgh in Pennsylvania, presented these results at the 2015 BMT Tandem Meetings. [Read Article]

Ibrutinib demonstrates efficacy in CLL after allo-HSCT

HT Staff Read Article
Published: 02/20/15

Prescription medications
Photo courtesy of CDC

Ibrutinib can produce favorable results in heavily pretreated patients with chronic lymphocytic leukemia (CLL) who have undergone allogeneic transplant, according to studies presented at the 2015 BMT Tandem Meetings. One study showed that ibrutinib prompted an 88% overall response rate (ORR) in 16 patients with relapsed/refractory CLL. Another analysis showed that ibrutinib can promote full donor chimerism and resolution of chronic graft-vs-host disease (GVHD). [Read Article]

Predicting outcomes of allo-HSCT in ALL

Jen Smith Read Article
Published: 02/19/15

Preparing HSCs for transplant
Photo by Chad McNeeley

A retrospective study has revealed a few factors that may predict outcomes of allogeneic hematopoietic stem cell transplant (allo-HSCT) in adults with acute lymphoblastic leukemia (ALL). The study showed that cytogenetics at diagnosis did not impact survival rates, although having high-risk cytogenetics was associated with an increased incidence of relapse in patients who were transplanted in their first complete remission (CR1).  [Read Article]

Product ‘solves engraftment problem’ with UCBT

Jen Smith Read Article
Published: 02/18/15

Umbilical cord blood donation
Photo courtesy of NHS

A product that promotes CD34 expansion has solved the problem of poor engraftment associated with umbilical cord blood transplant (UCBT), according to a speaker at the 2015 BMT Tandem Meetings. John Wagner, MD, of the University of Minnesota, supported this statement with early results from trials of HSC835, cord blood units in which CD34 cells were expanded using the aryl hydrocarbon receptor antagonist StemRegenin 1. [Read Article]

Expanded MSCs can treat severe aGVHD

HT Staff Read Article
Published: 02/18/15

Mesenchymal stem cells

Infusions of expanded mesenchymal stem cells (MSCs) can treat severe, steroid-resistant, acute graft-vs-host disease (aGVHD) in pediatric patients, according to a study presented at the 2015 BMT Tandem Meetings. The MSC product, known as remestemcel-L, induced responses in all grades of aGVHD and all organ systems. Response at day 28 was associated with improved survival at day 100, and clinically significant toxicities were minimal, according to investigators. [Read Article]

Day 90 CR not a good endpoint for auto-HSCT, doc says

Jen Smith Read Article
Published: 02/17/15

Patient receives chemotherapy
Photo by Rhoda Baer

A phase 3 study comparing conditioning regimens in multiple myeloma patients undergoing autologous transplant has yielded counterintuitive results. Patients who received busulfan plus melphalan (bu-mel) had a lower complete response (CR) rate at 90 days and a higher rate of grade 3-4 non-hematologic toxicity, compared to patients who received melphalan (mel) alone. However, patients in the bu-mel arm enjoyed significantly longer progression-free survival (PFS). [Read Article]


    {icon} {author} Read Article
    Published: {pubDate}